Novogen (Nasdaq: NVGN) announces completion of screening of its second generation of super-benzopyrans in its ongoing drug discovery platform.

This article: 253 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE